Cancer immunotherapy biotech Argos Therapeutics sets terms for $60 million IPO


Shutterstock photo

Argos Therapeutics, which is developing immunotherapies for the treatment of cancer and HIV, announced terms for its IPO on Tuesday. The Durham, NC-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Argos Therapeutics would command a fully diluted market value of $247 million.

Argos Therapeutics, which was founded in 1997 and booked $5 million in sales for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol ARGS. Argos Therapeutics initially filed confidentially on November 12, 2013. Piper Jaffray, Stifel and JMP Securities are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ARGS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by